The InTime Trial aims to assess the effects of the investigational drug, CT38, in terms of its safety and effectiveness in treating ME/CFS. There will be 18 people between 18 and 60 years of age enrolled in this study and participation will last up to approximately 4 months. Who: Dr. Lucinda Bateman, Located in Salt
Researchers from Stanford University aim to evaluate the endocrine system in female ME patients to learn how the hypothalamic-pituitary-adrenall (HPA) axis functions in ME/CFS patients. They will do this by evaluating antibodies in 60 ME/CFS cases and through basic endocrine testing. Who: Dr. Montoya at Stanford University is collaborating with Dr. De Bellis at Secondary University at Naples to
Cornell Center for Enervating Neuroimmune Disease aims to collect brain images (MRSs) from individuals with ME to study oxidative stress and neuroinflammation. Dr. Dikoma Shungu hopes to identify possible biomarkers for ME as well as add to the overall understanding of the disease. Who: Cornell Center for Enervating Neuroimmune Disease is collecting information from both ME patients
The Institute of NeuroImmune Medicine is collecting genetic data from 23andme or ancestry.com for 10,000 patients. Their aim is to generate computer learning programs will search for biomarkers that can be used to develop drug targets and diagnostic tests. Who: Dr. Klimas and Dr. Bested at NSU (Institute of Neuro Immune Medicine) When: Ongoing What: Click here to learn more. When: Ongoing
Brain tissue banks are able to provide ME researchers with samples to keep their research moving forward; Dr. Montoya and Dr. Plowey are accepting brain tissue from ME patients postmortem. Studying the brain tissue of ME patients is an important part of understanding more about the disease overall. Who: Dr. Montoya and Dr. Plowey at Stanford
